Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity.
Sam J, Colombetti S, Fauti T, Roller A, Biehl M, Fahrni L, Nicolini V, Perro M, Nayak T, Bommer E, Schoenle A, Karagianni M, Le Clech M, Steinhoff N, Klein C, Umaña P, Bacac M. Sam J, et al. Among authors: umana p. Front Oncol. 2020 Nov 30;10:575737. doi: 10.3389/fonc.2020.575737. eCollection 2020. Front Oncol. 2020. PMID: 33330050 Free PMC article.
Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies.
Niederfellner G, Lammens A, Mundigl O, Georges GJ, Schaefer W, Schwaiger M, Franke A, Wiechmann K, Jenewein S, Slootstra JW, Timmerman P, Brännström A, Lindstrom F, Mössner E, Umana P, Hopfner KP, Klein C. Niederfellner G, et al. Among authors: umana p. Blood. 2011 Jul 14;118(2):358-67. doi: 10.1182/blood-2010-09-305847. Epub 2011 Mar 28. Blood. 2011. PMID: 21444918 Free article.
Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
Croasdale R, Wartha K, Schanzer JM, Kuenkele KP, Ries C, Mayer K, Gassner C, Wagner M, Dimoudis N, Herter S, Jaeger C, Ferrara C, Hoffmann E, Kling L, Lau W, Staack RF, Heinrich J, Scheuer W, Stracke J, Gerdes C, Brinkmann U, Umana P, Klein C. Croasdale R, et al. Among authors: umana p. Arch Biochem Biophys. 2012 Oct 15;526(2):206-18. doi: 10.1016/j.abb.2012.03.016. Epub 2012 Mar 21. Arch Biochem Biophys. 2012. PMID: 22464987
Response to: monoclonal antibodies targeting CD20.
Klein C, Lammens A, Schäfer W, Georges G, Schwaiger M, Mössner E, Hopfner KP, Umaña P, Niederfellner G. Klein C, et al. Among authors: umana p. MAbs. 2013 May-Jun;5(3):337-8. doi: 10.4161/mabs.24108. Epub 2013 Mar 14. MAbs. 2013. PMID: 23493087 Free PMC article. No abstract available.
Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.
Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, Muth G, Ziegler-Landesberger D, Van Puijenbroek E, Lang S, Duong MN, Reslan L, Gerdes CA, Friess T, Baer U, Burtscher H, Weidner M, Dumontet C, Umana P, Niederfellner G, Bacac M, Klein C. Herter S, et al. Among authors: umana p. Mol Cancer Ther. 2013 Oct;12(10):2031-42. doi: 10.1158/1535-7163.MCT-12-1182. Epub 2013 Jul 19. Mol Cancer Ther. 2013. PMID: 23873847
A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
Schanzer JM, Wartha K, Croasdale R, Moser S, Künkele KP, Ries C, Scheuer W, Duerr H, Pompiati S, Pollman J, Stracke J, Lau W, Ries S, Brinkmann U, Klein C, Umana P. Schanzer JM, et al. Among authors: umana p. J Biol Chem. 2014 Jul 4;289(27):18693-706. doi: 10.1074/jbc.M113.528109. Epub 2014 May 19. J Biol Chem. 2014. PMID: 24841203 Free PMC article.
112 results